Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 90

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 90
---
 salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. We record accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, we accrue the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial. Upfront costs, such as costs associated with setting up clinical trial sites for participation in the trials, are expensed immediately once incurred as research and development expenses. Stock-based Compensation We recognize the compensation expense related to stock options, third -partywarrants, and restricted stock unit (“RSU”) awards granted, based on the estimated fair value of the awards on the date of grant. The fair value of employee stock options and third -partywarrants are generally determined using the Black -Scholesoption -pricingmodel using various inputs, including estimates of historic volatility, term, risk -freerate, and future dividends. The grant date fair value of the stock -basedawards, which have graded vesting, is recognized using the straight -linemethod over the requisite service period of each stock -basedaward, which is generally the vesting period of the respective stock -basedawards. The Company recognizes forfeitures as they occur. As of December 31, 2024, there were 3 Rollover RSU awards vested and unissued and 64 stock options outstanding. Recent Accounting Pronouncements See Note 2 to our consolidated financial statements included in our Annual Report on Form 10 -Kfor the year ended December31, 2024 for more information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results of operations. 55 DESCRIPTION OF THE COMPANY’S BUSINESS Throughout this section, unless otherwise noted, “we,” “us,” “our,” “Revelation” and the “Company” refer to Revelation Biosciences, Inc. and its subsidiary. Overview Revelation is a clinical -stagelife science company that is focused on rebalancing inflammation to optimize health